Legend Biotech Corporation
legendbiotech.comWhat Do They Do?
Develops and commercializes cell therapies for people with cancer, including CARVYKTI for multiple myeloma, while developing additional therapies for cancer and autoimmune conditions.
20-F for FY2025, filed Mar 10, 2026We are a global biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of novel cell…View ↗
On February 28, 2022, cilta-cel was approved by the FDA under the trademark CARVYKTI for the treatment of adults with RRMM who have…View ↗
In addition to cilta-cel, we have a broad portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers…View ↗
Who Are Their Customers?
CARVYKTI customers buy from Janssen outside Greater China and from Legend in Greater China.
20-F for FY2025, filed Mar 10, 2026The Company and Janssen share equally profits on sales of CARVYKTI in all areas other than the People's Republic of China, including the…View ↗
Do Revenues Turn Into Profits?
No. It lost $296.8M in .
20-F for FY2025, filed Mar 10, 2026
20-F for FY2025, filed Mar 10, 2026
−$296.8MView ↗
How Are They Changing?
Commercialization
The earlier report described Legend as primarily clinical-stage while noting CARVYKTI's launch; the latest describes an established sales, marketing and operating infrastructure.
20-F for FY2022, filed Mar 30, 2023 20-F for FY2025, filed Mar 10, 2026
Broader cell therapy pipeline
The earlier report described autologous CAR-T candidates and an allogeneic CAR-T candidate; the latest also lists CAR-NK, in-vivo CAR-T and autoimmune programs.
20-F for FY2022, filed Mar 30, 2023 20-F for FY2025, filed Mar 10, 2026In addition to cilta-cel, we have a broad portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers…View ↗
Manufacturing facilities
The earlier report said it was building manufacturing facilities in the United States, EU and China; the latest says it has facilities in the United States and Belgium for commercial supply.
20-F for FY2022, filed Mar 30, 2023 20-F for FY2025, filed Mar 10, 2026We have built our company around overcoming the challenges associated with CAR-T cell therapy development through deploying our…View ↗
We have built our company around overcoming the challenges associated with cell therapy development through deploying our fully-integrated…View ↗
Who Do They Compete With?
Competes with Novartis, Kite, Bristol-Myers Squibb, bluebird bio, Arcellx, Autolus Therapeutics, Johnson & Johnson, Caribou Biosciences, CARsgen Therapeutics, AstraZeneca, IASO Biotechnology, Oricell Therapeutics, Roche, Kelonia, EsoBiotech, Interius, Amgen, Regeneron Pharmaceuticals, GSK, and Innovent
20-F for FY2025, filed Mar 10, 2026Novartis' Kymriah is approved for the treatment of children and young adults with ALL that is refractory or has relapsed at least twice and…View ↗
Loading...
